ClinVar Miner

Submissions for variant NM_000427.3(LORICRIN):c.673dup (p.Tyr225fs)

dbSNP: rs1571081028
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV001008534 SCV001168306 likely pathogenic not provided 2019-01-14 criteria provided, single submitter clinical testing The c.673dupT variant in the LOR gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. It was also not observed in large population cohorts (Lek et al., 2016). The c.673dupT variant causes a frameshift starting with codon Tyrosine 225, changes this amino acid to a Leucine residue, and creates a Stop codon at position 111 of the new reading frame, denoted p.Tyr225LeufsX111. This frameshift variant replaces the last 88 amino acid residues of the C-terminus of lorcrin with aberrant residues and elongates the protein. Other pathogenic frameshift variants in the tail region have been previously reported in patients with loricrin keratoderma, which were shown to cause accumulation of lorcrin in the nucleus (Stenson et al., 2014; Khalil et al., 2017). We interpret c.673dupT as a likely pathogenic variant.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.